AI-enabled tumor assessment is transforming how treatment response is evaluated in oncology clinical trials. By moving beyond manual RECIST measurements, artificial intelligence in medical imaging delivers more consistent, scalable, and sensitive evaluation of tumor response—supporting faster and smarter oncology drug development.
Through the ai.RECIST initiative led by Friends of Cancer Research, industry leaders collaborate to define a standards-based framework for AI-powered RECIST assessments. This ensures AI tumor measurement tools are validated, interpretable, and fit for regulatory decision-making.
The white paper outlines a stepwise path for responsible AI integration in oncology imaging. By leveraging existing clinical trial imaging data and harmonized methodologies, AI-driven tumor response evaluation can enhance traditional RECIST workflows and accelerate clinical research.